Key result
A retrospective analysis of 132,417 patients was conducted to establish age- and sex-specific 99th percentiles for the SMC cTnI test, which previously used a uniform 99th percentile of 7.1 ng/L.
This study aimed to establish age- and sex-specific 99th percentiles for a high-sensitivity cardiac troponin I assay using a large community-based cohort.
Answers are grounded in this paper and cite their sources.
Age- and sex-specific 99th percentiles for SMC cTnI may refine AMI diagnosis in select patients; leaves open whether adoption improves outcomes.
To the Editor: Cardiac troponin I (cTnI)1 is routinely used to aid in the diagnosis of acute myocardial infarction. Few available cardiac troponin assays have adopted 99th percentiles based on patient demographics. However, there is growing evidence of age and sex differences for cTnI and cardiac troponin T (cTnT), especially when using high-sensitivity cardiac troponin assays, with sex-dependent 99th percentiles being recommended for clinical care (1–3). The Single Molecule Counting (SMCTM) cTnI test (Singulex) can measure cTnI in nearly all healthy individuals (4). We sought to establish the 99th percentile for the SMC cTnI test by deriving an objective definition of “healthy” from >100000 patient results. SMC cTnI is a laboratory-developed test (not cleared by the Food and Drug Administration). The test is a quantitative fluorescent 1-step sandwich immunoassay developed to measure human cTnI concentrations in separated EDTA plasma (5). The lower limit of quantification (LLoQ) was 0.40 ng/L (the lowest standard concentration with back-interpolated recovery bias <20% and CV <20%). The LLoQ was the lowest reliable concentration and the lowest result clinically reported. SMC cTnI results were retrospectively mined from the Singulex patient database (n = 132417) containing data from all-comer community-based patients at risk for cardiovascular disease whose physicians ordered this test between 2013 and 2014. The former 99th percentile was 7.1 ng/L and applied to all patients regardless of age or sex. Samples were collected from 21 states within the continental US and shipped overnight at 2 to 8 °C to the CLIA-certified Singulex Clinical Laboratory (SCL) for analysis on the Erenna® system.
No takes yet. Share an insight, caveat, or question.
Estis et al. (2017) conducted a letter in At risk for cardiovascular disease (n=132,417). Single Molecule Counting (SMC) cTnI test was evaluated on 99th percentile for the SMC cTnI test. A retrospective analysis of 132,417 patients was conducted to establish age- and sex-specific 99th percentiles for the SMC cTnI test, which previously used a uniform 99th percentile of 7.1 ng/L.
Synapse has enriched 10 related papers. Consider them for comparative context: